+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Control of anticoagulation with vitamin K antagonists: overestimation of median time in therapeutic range when assessed by linear interpolation



Control of anticoagulation with vitamin K antagonists: overestimation of median time in therapeutic range when assessed by linear interpolation



Thrombosis and Haemostasis 116(4): 679-686



Patients receiving vitamin K-antagonists are monitored by regular assessment of the International Normalized Ratio (INR). There are two popular methods for therapeutic control of anticoagulation in patient groups: 1) Time in Therapeutic Range (TTR) assessed by linear interpolation of successive INR measurements; 2) the cross-sectional proportion (CSP) of all patients' last INRs within range. The purpose of the present study is to compare the two methods using data from 53 Dutch Thrombosis Centres and to develop a semi-quantitative model for TTR based on different types of INR change. Different groups of around 400,000 patients in four consecutive years were evaluated: patients in the induction phase, short-term, long-term, low-target range, high-target range, receiving either acenocoumarol or phenprocoumon, and performing self-management. Each Centre provided TTR and CSP results for each patient group. TTR and CSP were compared using the Wilcoxon signed-rank test. Separately, we analysed the relationship between consecutive INR results regarding in or out of range and their frequency of occurrence in patients of two different cohorts. Good correlation was observed between TTR and CSP (correlation coefficient 0.694-0.950 in low-target range). In long-term acenocoumarol patients (low-target range) the median TTR was significantly higher than CSP (80.0 % and 78.7 %, respectively; p<0.001). In long-term phenprocoumon patients (low-target range) there was no significant difference between median TTR (83.0 %) and median CSP (82.6 %). In conclusion, the correlation between TTR assessed by linear interpolation and CSP was good. TTR assessed by linear interpolation was higher than CSP in patients on acenocoumarol.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057504026

Download citation: RISBibTeXText

PMID: 27384264

DOI: 10.1160/th16-03-0184


Related references

Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation. American Heart Journal 200: 32-36, 2018

Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina. Clinical and Applied Thrombosis/Hemostasis 23(5): 445-453, 2017

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children. Journal of Thrombosis and Haemostasis 9(5): 1090-1092, 2011

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2331-2332, 2012

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2332-2333, 2012

Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Canadian Journal of Cardiology 32(10): 1247.E23-1247.E28, 2016

Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review. Cardiovascular and Hematological Disorders Drug Targets 17(2): 105-110, 2017

Quality of management of oral anticoagulation as assessed by time in therapeutic INR range in elderly and younger patients with low mean years of formal education: a prospective cohort study. Age and Ageing 40(3): 375-381, 2011

Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. Journal of Thrombosis and Thrombolysis 35(3): 333-335, 2013

Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients. Drugs and Aging 35(6): 569-574, 2018

Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study. Clinical Therapeutics 34(7): 1511-1520, 2012

Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. Journal of Thrombosis and Thrombolysis 31(3): 249-258, 2011

The value of time in therapeutic range in the prediction of outcomes at a populational level in patients treated with vitamin K antagonists. Current Medical Research and Opinion 34(3): 499-500, 2018

Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. Europace 17(8): 1223-1228, 2015

Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. Clinical and Applied Thrombosis/Hemostasis 23(6): 685-695, 2017